MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

8.32 -0.83

Overview

Share price change

24h

Current

Min

8.23

Max

8.45

Key metrics

By Trading Economics

Income

-13M

-27M

Sales

14M

132M

EPS

-0.13

Profit margin

-20.371

Employees

580

EBITDA

-13M

-1.2M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+75.57% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

-155M

1.6B

Previous open

9.15

Previous close

8.32

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Apr 2025, 23:27 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 Apr 2025, 23:07 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 Apr 2025, 23:03 UTC

Earnings

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 Apr 2025, 23:47 UTC

Market Talk

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 Apr 2025, 23:17 UTC

Earnings

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 Apr 2025, 23:17 UTC

Earnings

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 Apr 2025, 23:13 UTC

Earnings

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 Apr 2025, 23:13 UTC

Earnings

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 Apr 2025, 23:13 UTC

Earnings

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 Apr 2025, 23:13 UTC

Earnings

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 Apr 2025, 23:08 UTC

Earnings

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 Apr 2025, 23:08 UTC

Earnings

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 Apr 2025, 23:08 UTC

Earnings

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 Apr 2025, 23:04 UTC

Earnings

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 Apr 2025, 23:04 UTC

Earnings

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 Apr 2025, 23:04 UTC

Earnings

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 Apr 2025, 23:04 UTC

Earnings

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 Apr 2025, 23:00 UTC

Earnings

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 Apr 2025, 23:00 UTC

Earnings

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 Apr 2025, 23:00 UTC

Earnings

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 Apr 2025, 23:00 UTC

Earnings

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 Apr 2025, 22:57 UTC

Top News

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 Apr 2025, 22:55 UTC

Earnings

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 Apr 2025, 22:55 UTC

Earnings

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 Apr 2025, 22:55 UTC

Earnings

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 Apr 2025, 22:52 UTC

Earnings

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 Apr 2025, 22:52 UTC

Earnings

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 Apr 2025, 22:52 UTC

Earnings

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 Apr 2025, 22:52 UTC

Earnings

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 Apr 2025, 22:46 UTC

Earnings

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

75.57% upside

12 Months Forecast

Average 14.73 USD  75.57%

High 30 USD

Low 8 USD

Based on 11 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.